Status:
COMPLETED
A Trial of CM-AT in Children With Autism
Lead Sponsor:
Curemark
Conditions:
Autism
Eligibility:
All Genders
3-8 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to determine whether CM-AT is safe and effective in treating the core symptoms of autism.
Detailed Description
Autism is currently a significant cause of disability in the pediatric population. Treatment is based upon the observation that many children with autism do not digest protein. CM-AT is a proprietary ...
Eligibility Criteria
Inclusion
- Meets the current Diagnostic and Statistical Manual for Mental Disorders (DSM-IV-TR) diagnostic criteria for autistic disorder (AD)
Exclusion
- Patient weighing \< 11kg (24.2 lbs.)
- Demonstrated previous allergy to porcine (pork) products
- Previous history of severe head trauma or stroke, seizure within one year of entering study or uncontrolled systemic disease
- Diagnosis of: HIV, cerebral palsy, endocrine disorder, pancreatic disease
- Within 30 days of starting the study, certain supplementation, chelation or dietary restriction (a 30 day washout period would be required for inclusion)
- Use of of any stimulant medication must be discontinued 5 days prior to entering the study.
- Subject must have a stable dose of SSRI's for at least 30 days.
Key Trial Info
Start Date :
May 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2011
Estimated Enrollment :
182 Patients enrolled
Trial Details
Trial ID
NCT00881452
Start Date
May 1 2009
End Date
September 1 2011
Last Update
April 19 2018
Active Locations (19)
Enter a location and click search to find clinical trials sorted by distance.
1
Southwest Autism Research and Resource Center
Phoenix, Arizona, United States, 85006
2
University of California, Davis, M.I.N.D. Institute
Sacramento, California, United States, 95817
3
University of California, San Francisco
San Francisco, California, United States, 94143
4
Neuropsychiatric Research Center of Orange County
Santa Ana, California, United States, 92701